Conjugates for immunotherapy

Patent metadata

Field	Value
Publication number	US-10449227-B2
Application number	US-201515321316-A
Country	US
Kind code	B2
Filing date	Jun 26, 2015
Priority date	Jun 27, 2014
Publication date	Oct 22, 2019
Grant date	Oct 22, 2019

Abstract

The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.

First claim

We claim:

1. A molecular conjugate comprising:
a) a luteinizing hormone releasing hormone (LHRH) peptide antagonist; and
b) an immune effector molecule conjugated to the antagonist, wherein the immune effector molecule is selected from the group consisting of CD86, 41BBL, OX40L, or a combination of two or three thereof, or wherein the immune effector molecule is selected from the group consisting of CD40L, 41BB, CCL21, IL-12, or a combination of two or more thereof.

2. The molecular conjugate of claim 1 , wherein two or more antagonist molecules are conjugated to the immune effector molecule.

3. The molecular conjugate of claim 1 , wherein two or more immune effector molecules are conjugated to the antagonist molecule.

4. The molecular conjugate of claim 3 , wherein the two or more immune effector molecules are a single type of immune effector molecule.

5. The molecular conjugate of claim 3 , wherein the two or more immune effector molecules are two or more different types of effector molecules.

6. The molecular conjugate of claim 1 , further comprising an imaging agent.

7. The molecular conjugate of claim 1 , further comprising:
a pharmaceutically acceptable carrier.

8. A method of treating a cancer which expresses LHRH receptor, the method comprising administering to a subject in need thereof a therapeutically effective amount of a molecular conjugate according to claim 1 .

9. A method for delivering a molecular conjugate to a cancer cell expressing LHRH receptor, the method comprising administering to the cell in vitro or in vivo a molecular conjugate of claim 1 .

Assignees

• H Lee Moffitt Cancer Ct & Res
• Univ South Florida

Inventors

• Mclaughlin Mark
• Morse David L
• Pilon-Thomas Shari
• Antonia Scott

Classifications

• A61K38/08 Primary

  Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K49/0032

  Methine dyes, e.g. cyanine dyes · CPC title

• A61K47/646

  the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines · CPC title

• A61K2039/60

  characteristics by the carrier linked to the antigen · CPC title

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title